作者: Giovanni Selvaggi , Giorgio V. Scagliotti
DOI: 10.1016/J.CRITREVONC.2005.03.011
关键词: Medicine 、 Bone metastasis 、 Pathologic fracture 、 Oncology 、 Bone Density Conservation Agents 、 Disseminated disease 、 Cancer 、 Internal medicine 、 Clinical trial 、 Basic research 、 Radiation therapy 、 Surgery
摘要: The presence of bone metastases is indicative disseminated disease and typically indicates a short-term prognosis in cancer patients. Palliation symptoms the primary goal therapy, with multidisciplinary efforts yielding best results. New classes drugs, such as bisphosphonates that significantly increase time to first skeletal-related event (SRE), represent useful tools for treatment metastases. While optimal duration therapy needs be defined, there clinical benefit derived from use this class agents. A potential role prevention under current evaluation trials encompassing different solid tumor types. In combination ongoing trials, basic research identify novel targets cells-bone microenvironment will further define future strategies